This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=119 http://www.lsis.com/goto/r119/rss 2012-05-21T11:11:15+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=119 OBJECTIVE:To investigate the rate of seropositivity of anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab in the postmarketing setting and to assess anti-JCV serostatus in samples obtained before diagnosis of progressive multifocal leukoencephalopathy (PML). METHODS:This was a blinded, retrospective cross-sectional and longitudinal analysis for anti-JCV antibodies using a confirmatory 2-step ELISA on 2,782 blood samples obtained from 2,253 (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 TORONTO, May 14, 2012 (GLOBE NEWSWIRE) - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that a mini-symposium entitled "The Emerging Clinical Profile of Oral Scyllo-inositol (ELND005) in Alzheimer's Disease: A Dual Mechanism of Action?" was held on Saturday, May 12th, 2012 at the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapies. Elan Pharmaceuticals, Inc. has responsibility for the development and (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 The purpose of this study is to look at the effect of 2 different corticosteroid treatment schedules in the setting of Immune Reconstitution Inflammatory Syndrome (IRIS) in patients who have developed Progressive Multifocal Leukoencephalpathy (PML) while on treatment with natalizumab. |-| High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab |-| Biogen Idec, Elan Pharmaceuticals |-| United (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substances (cells) found in the immune (protective) system. Blood test will be drawn by doing the following: Use a new method called the Immuknow Test to see if this method will help to better understand how MS medicines work. Measure certain levels of immune cells in a new way, to see if it this will (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 Define the sero prevalence of JCV Antibody in the MS population and potentially stratify patients into lower or higher risk for developing PML based on antibody status. |-| JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2 |-| Biogen Idec, Elan Pharmaceuticals |-| United States, Missouri There are multiple sites throughout the United States in this study. Please contact United BioSource Corporation (UBC) @ (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201. |-| A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease |-| Elan Pharmaceuticals, Transition Therapeutics |-| Show 38 Study Locations text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS). |-| A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis |-| Elan Pharmaceuticals |-| United States, California Research Site Berkeley, (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 The purpose of the study is to explore if mefloquine works to slow or stop the worsening of PML and to better understand PML. We will measure if mefloquine is working by determining if it reduces the level of JC virus in spinal fluid, as well as, clinical and MRI measures. |-| A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy(PML) |-| Biogen Idec, Elan Pharmaceuticals |-| Show 28 Study Locations text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 The pharmacokinetic (PK) profile of Tysabri in patients has been observed following 1 dose and after 6 consecutive doses. The primary purpose of this study is to observe the PK profile of Tysabri in patients who have been treated with Tysabri for at least 12 months (i.e., after achievement of steady state). To support this investigation, the pharmacodynamic (PD) profile will also be established in this population by assessing 4 integrin saturation. The dosing regimen will be consistent with (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 Phase 3b, multicenter, international, randomized, double-blind, placebo-controlled study to assess the efficacy of natalizumab in approximately 856 SPMS subjects who are exhibiting disease progression independent of relapses. Subjects will be randomized to receive either natalizumab 300 mg or placebo intravenously (IV) every 4 weeks (q4wk) for 96 weeks. This study will be conducted in subjects between the ages of 18 and 58, inclusive, with a diagnosis of SPMS for at least 2 years, an EDSS (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab. The main purpose of this study is to find out the following, when participants stop taking natalizumab for 24 weeks: how quickly the effects that natalizumab has on the immune system disappear, when MS symptoms return, and if other drugs for MS may help control MS symptoms during the (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 The aim of this study is to evaluate the evolution of walking capacity as measured by T100T, T25FW, MWD and EDSS during the first year of therapy with natalizumab. |-| A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients.TIMER Study. |-| Biogen Idec, Elan Pharmaceuticals |-| Belgium Biogen Idec Investigative Site Liege, Belgium, B-4000 Mexico Biogen Idec (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 Study conducted to define the prevalence of Serum JC Antibody in relapsing MS patients receiving Tysabri or being considered for such treatment. Analytically validate the JCV antibody assay in a plasma matrix. |-| JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1 |-| Biogen Idec, Elan Pharmaceuticals |-| United States, Colorado Research Site Aurora, Colorado, United States, 80045 United States, Georgia Research Site (…) text/html http://www.clinicaltrials.gov ClinicalTrials.gov http://www.lsis.com/channels/?query=119 The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics or an Elan Corporation sponsored protocol. Subjects are eligible regardless of whether they received active drug or placebo during their participation in the previous study. |-| Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 Oslo May 2nd 2012 Anders Lönneborg Ph.D., has been chosen as recipient of the 2011 Alzheimer Award presented by the Journal of Alzheimer s Disease in recognition of his outstanding work, œA Novel Blood Test for the Early Detection of Alzheimer s Disease , (J Alzheimers Dis 23, 121-129, 2011) by A. Lönneborg et al. œMy co-authors and I are extremely pleased to have been chosen by a distinguished group of peers as the recipients of this year s Journal of Alzheimer s Disease award for (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 OSLO, Norway-(BUSINESS WIRE)-Regulatory News: JAD award 2012 (http:/mb.cision.com/Public/115/9254407/bf218412933ba189.pdf) Highly ranked Journal of Alzheimer's Disease (JAD) today announced that Anders Lönneborg and DiaGenic has been chosen as recipient of the 2011 Alzheimer Award. The article «A Novel Blood Test for the Early Detection of Alzheimer's Disease" which covers the development of the diagnostic Alzheimer test ADtect was voted for by a majority of the Associate Editors of JAD (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 WESTON, Mass. & DUBLIN-(BUSINESS WIRE)-Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced findings from several studies of TYSABRI (natalizumab) evaluating its long-term safety and efficacy in the treatment of multiple sclerosis (MS) across the course of disease and impact on MS-related symptoms such as fatigue. These data, as well as data relating to the companies risk stratification algorithm as a way to help enable individual benefit risk assessment for (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc (NYSE: ELN) announced today that it will present at the Deutsche Bank 37th Annual Healthcare Conference on Tuesday, May 8, 2012 at 10.40 a.m. Eastern Standard Time, 3:40pm Greenwich Mean Time. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=119 Introduction: Alzheimer's disease is a devastating neurodegenerative disorder for which no disease-modifying therapy exists. The amyloid hypothesis, which implicates A? as the toxin initiating a biological cascade leading to neurodegeneration, is the most prominent theory concerning the underlying cause of the disease. BACE1 is one of two aspartyl proteinases that generate A?, thus inhibition of BACE1 has the potential to ameliorate the progression of Alzheimer's disease by abating the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 A patient taking Novartis AG s Gilenya multiple sclerosis pill has been diagnosed with a potentially deadly brain infection. The patient previously took Tysabri, an injection from Weston-based Biogen Idec Inc. and Elan Corp., Novartis said in an e-mailed statement. Tysabri increases the risk of the viral infection, known as progressive multifocal leukoencephalopathy, that usually leads to death or severe disability, according to a warning the drug s label has carried since 2006. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Thursday, April 26, 2012 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan s first quarter 2012 financial results, which will be released before the European and U.S. financial markets open. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=119 Bioanalysis. |-| Barbour R, Bova MP. |-| Director of Antibody Technologies, Neotope Biosciences, a division of Elan Pharmaceuticals Inc., 650 Gateway Blvd, San Francisco, CA, USA. robin.barbour@neotopebio.com. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 NOKOMIS, Fla.-(BUSINESS WIRE)-Parkinson s disease is the core focus of the The Michael J. Fox Foundation. Rainbow BioSciences (OTCBB: RBCC) intends to join the Foundation in the fight against Parkinson s disease when it signs a letter of intent with an advanced therapy developer within the next few days, and with good reason: There could be 12 million people suffering from the disease by 2032. Thanks in no small part to the high profile of its A-list namesake, the Michael J. Fox Foundation (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 COPENHAGEN, Denmark-(BUSINESS WIRE)-Unilabs today announced the one-year status on testing in Europe and several other markets outside Europe with the CE marked ELISA test STRATIFY JCV. STRATIFY JCV is an important tool used to help enable individual benefit-risk assessment for patients with multiple sclerosis (MS) by identifying their anti-JC virus (JCV) antibody status. In 2011, Unilabs was selected by Biogen Idec and Elan Corporation, plc to provide STRATIFY JCV testing services for the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc (NYSE: ELN) today raised approximately $381 million in net proceeds from the sale of 76% (24.15 million ordinary shares) of its shareholding in Alkermes plc (NASDAQ: ALKS), net of underwriter fees. These proceeds further strengthen Elan s cash balances and capital structure. In September 2011, when Elan combined its Elan Drug Technology (EDT) business with Alkermes Inc, Elan received $500 million in cash and 31.9 million ordinary shares in the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Alkermes plc (NASDAQ: ALKS) ( œAlkermes ) today announced the completion of an underwritten public offering of 24,150,000 ordinary shares held by a subsidiary of Elan Corporation, plc ( œElan ) at a price to the public of $16.50 per share, which includes 3,150,000 ordinary shares in connection with the full exercise by the underwriters of their option to purchase additional shares. Alkermes did not receive any proceeds from the offering, and its total number of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Alkermes plc (NASDAQ: ALKS) ( œAlkermes ) today announced the pricing of an underwritten public offering of 21,000,000 ordinary shares held by a subsidiary of Elan Corporation, plc ( œElan ) at a price to the public of $16.50 per share. Alkermes will not receive any proceeds from the offering and its total number of ordinary shares outstanding will not change as a result of the offering. In addition, Elan has granted the underwriters a 30-day option to purchase (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Alkermes plc (NASDAQ: ALKS) ( œAlkermes ) today announced that it has commenced an underwritten public offering, subject to market and other conditions, of 13,900,000 ordinary shares held by a subsidiary of Elan Corporation, plc ( œElan ), pursuant to an effective shelf registration statement. As part of the offering, Elan intends to grant the underwriters a 30-day option to purchase up to an additional 2,085,000 ordinary shares. Alkermes will not receive any (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-The Chairman of Elan (NYSE:ELN), Mr. Robert Ingram today provided an update on CEO succession: œOn June 3, 2010, Elan communicated that, as part of its prudent executive succession management process, Kelly Martin, CEO, and the Board of Directors agreed that by May 1, 2012, Kelly would have successfully completed his commitment and overall duty as CEO to the company that he had served since January 2003. At the time, the date was agreed to enable the Board and Kelly (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc (NYSE: ELN) today announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2011. The Form 20-F is available on Elan's website at www.elan.com. Elan will provide to all holders of Elan securities, upon request and free of charge, a hard copy of our complete audited financial statements included in our Form 20-F. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc (NYSE: ELN) announced today that it will present at the Cowen & Co., 32nd Annual Healthcare Conference on Tuesday, March 6, 2012 at 9.20 a.m. Eastern Standard Time and 2.20 p.m. Greenwich Mean Time. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Alkermes plc (NASDAQ: ALKS) today filed a resale shelf Registration Statement on Form S-1 with the Securities and Exchange Commission ( œSEC ) relating to the potential future sales by a subsidiary of Elan Corporation, plc ( œElan ) of up to 31,900,000 ordinary shares of Alkermes plc ( œAlkermes ), pursuant to the shareholder s agreement between Alkermes and Elan entered into in connection with the business combination of Elan s drug technology unit and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results. œIn 2011, Elan made substantial progress across all areas of the company,  said Mr. Kelly Martin, chief executive officer. œThe strategic positioning of the underlying business post the sale of EDT to Alkermes further strengthened our fundamentals from a financial and risk point of view. In addition, the continued growth in Tysabri, along with the label updates allowing a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=119 BACKGROUND: Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid ?. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal effusions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H). Our aim was to investigate the incidence of ARIA during treatment with bapineuzumab, and evaluate associated risk factors. METHODS: Two (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 LONDON-(BUSINESS WIRE)-Citi today announced that its Global Transaction Services business, acting through Citibank N.A., has been appointed by Elan Corporation, plc ( œElan ), a leading biotechnology company headquartered in Ireland, as the successor depositary bank for its American Depositary Receipt (ADR) program. Elan's ADRs trade on the New York Stock Exchange under the symbol 'ELN', with each ADR representing 1 ordinary share. Elan s ordinary shares are listed on the Irish Stock (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc (NYSE:ELN) announced today that it will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday February 15, 2012 at 2.00 p.m. Eastern Standard Time and 7.00 p.m. Greenwich Mean Time. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=119 : To assess multiple sclerosis (MS) patients' experience with natalizumab (TYSABRI, Biogen Idec, Inc. and Elan Pharmaceuticals, Inc.) in a clinical practice setting. |-| Patient. |-| Kamat SA, Rajagopalan K, Stephenson JJ, Agarwal S. |-| 1 HealthCore Inc., Wilmington, Delaware, USA 2 Biogen Idec, Cambridge, Massachusetts, USA. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Wednesday, February 8, 2012 at 8:30 a.m. Eastern Standard Time (EST), 1:30 p.m. Greenwich Mean Time (GMT) with the investment community to discuss Elan s fourth quarter and full-year 2011 financial results, which will be released before the European and U.S. financial markets open. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 WESTON, Mass. & DUBLIN-(BUSINESS WIRE)-Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for secondary-progressive multiple sclerosis (SPMS). According to the National Multiple Sclerosis Society, approximately half of all people initially diagnosed with relapsing-remitting multiple sclerosis (RRMS) - the most common form of multiple sclerosis (MS) - (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 WESTON, Mass. & DUBLIN-(BUSINESS WIRE)-Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoencephalopathy (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=119 ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease. ELND006 shows poor solubility and has moderate to high permeability, suggesting it is a Biopharmaceutics Classification System Class II compound. The poor absolute oral bioavailability of the compound in fasted dogs (F ?11%) is attributed to poor aqueous solubility. In addition, inhibiting amyloid precursor protein but not Notch cleavage is an important goal for gamma (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=119 ScienceDaily (Dec. 21, 2011) New research suggests that, in people who don't currently have memory problems, those with smaller regions of the brain's cortex may be more likely to develop symptoms consistent with very early Alzheimer's disease. The study is published in the December 21, 2011, online issue of Neurology , the medical journal of the American Academy of Neurology. See Also: Health & Medicine Alzheimer's Research Healthy Aging Cholesterol Mind & Brain Alzheimer's Dementia (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=119 Objective.? The safety and efficacy of intrathecal (IT) ziconotide was studied in a randomized, double-blind, placebo-controlled trial. Materials and Methods.? Patients (169 ziconotide, 86 placebo) with severe chronic nonmalignant pain unresponsive to conventional therapy and a visual analog scale of pain intensity (VASPI score) ? 50 mm were treated over a 6-day period in an inpatient hospital setting. Initial starting dose was 0.4 µg/hour and was titrated to analgesia or (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=119 Objective.? To determine the stability of admixtures combining ziconotide with morphine or hydromorphone under simulated intrathecal infusions. Materials and Methods.? Admixtures of ziconotide (25 µg/mL) with morphine or hydromorphone (both at 35 mg/mL) were stored in Medtronic SynchroMed II pumps at 37°C, and in control vials at 37°C and 5°C. Drug concentrations were determined using high-performance liquid chromatography. Results.? The ziconotide pump concentration with morphine (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN, Dec 12, 2011 (BUSINESS WIRE) - University College Dublin (UCD) and Elan Corporation plc, /quotes/zigman/170510/quotes/nls/eln ELN +2.46% today announced an initiative designed to create a leadership position in the global biotechnology industry. The cornerstone of this effort will be the establishment of Europe's first interdisciplinary Chair in the 'Business of Biotechnology' which will sit at the intersection of the UCD Smurfit Graduate School of Business and the UCD College of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc (NYSE: ELN) today provides an update on ELND005 (Scyllo-inositol). Elan has entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG. This agreement is fundamental to ensuring that a high quality supply of ELND005 will be available to support the advancement of the program. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 CAMBRIDGE, United Kingdom & DUBLIN-(BUSINESS WIRE)-The University of Cambridge and Elan Corporation plc. (NYSE: ELN) today announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England. The Cambridge-Elan Centre will provide a highly interdisciplinary environment uniquely positioned for delivering world-leading translational research focused on innovative therapies for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=119 NOKOMIS, Fla.-(BUSINESS WIRE)-Rainbow Coral Corp. (OTCBB:RBCC) announced today that it has established the headquarters of its new biotechnology division Rainbow BioSciences, LLC in Houston, Texas, home of the world s largest medical complex. The opportunities in Houston to develop new R&D partnerships and breakthroughs are unmatched anywhere else in the Southern U.S. We re very excited to set up shop and forge ahead with our new biotech initiatives. œWe targeted Houston from the beginning (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=119 Medford, MA, November 2, 2011 - At the annual meeting of the International Society for the Study of Xenobiotics (ISSX), Hepregen Corporation, and two of its pharmaceutical customers, Boehringer Ingelheim Pharmaceuticals, Inc. and Elan Pharmaceuticals presented new preclinical data in poster presentations that tested Hepregen's proprietary microliver technology platform, HepatoPac ¢, for predicting clearance of drugs which are slowly removed by the liver. Of the commercially available drugs (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=119 WESTON, Mass.-(BUSINESS WIRE)-Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results. This has been a quarter of tremendous accomplishments for Biogen Idec Third Quarter 2011 Highlights: Third quarter revenues increased 11% to $1.3 billion, compared to the third quarter of 2010. TYSABRI (natalizumab) revenues increased 26% year-over-year to $277 (…)